With Approvals Likely, Obesity Drugs Expected to Coexist
BioWorld Insight Contributing Writer
After positive recommendations from the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for both Vivus Inc.'s Qnexa (phentermine/topiramate) and Arena Pharmaceuticals Inc.'s lorcaserin, it looks like both drugs will get past the FDA on their second attempts.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST